SK Plasma’s new blood products manufacturing plant will provide a boost to Jakarta’s economy. (Photo by Praisaeng/Shutterstock)

SK Plasma, a South Korea-based biologic medicine company that develops and manufactures high-quality plasma-derived medicines, plans to invest $250m to build a new blood products manufacturing facility in Jakarta, the capital city of Indonesia.

The plasma fractionation facility will produce products such as immune globulin and albumin, used for patients with immunodeficiency diseases and haemophilia. The plant will be capable of producing one million litres of blood products per year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SK Plasma is a subsidiary of SK Discovery, which announced in December 2022 that it would be opening a bio strategy and investment division to be led by Kim Jung-hoon, the director of SK Chemicals’ research and development centre.